Literature DB >> 29892527

Conservative management of Oral Submucous Fibrosis in early and intermediate stage.

Sachin Rai1, Vidya Rattan1, Akshat Gupta1, Praveen Kumar1.   

Abstract

AIMS &
OBJECTIVE: To evaluate the efficacy of combined intralesional injection of Hyaloronidase and Triamcinolone with third molar removal in early and intermediate stage (Stage II & III) of Oral Submucous Fibrosis (OSMF) for improvement in mouth opening and hypersensitivity to food. STUDY
DESIGN: 48 patients in stage II & III OSMF were selected for the study. All the third molars were extracted in each patient followed by 6-8 doses of combined intralesional injection of Hyaloronidase and triamcinolone at 10 days interval targeting the fibrotic bands. Mouth opening and improvement in hypersensitivity to food was noted by numerical grading. The patients were followed for one year at regular intervals. The data was expressed as mean ± SD, and a probability (p) value of <0.05 was considered significant.
RESULTS: The initial mouth opening in Stage II patients (n = 27) was 30 ± 3.0 mm and in Stage III patients (n = 21) was 19 ± 3.5 mm and the increase in mouth opening at the end of treatment was 11.3 ± 1.9 mm and 10.2 ± 2.3 mm respectively. The mean improvement in hypersensitivity to food in both the groups was 2.9 and 2.2 respectively.
CONCLUSION: There is significant improvement in grade II patients in mouth opening and hypersensitivity to food. Grade III patients show variable improvement or no improvement wherein surgery becomes the only option. Third molar extraction helps in reducing inflammation and fibrosis in the retromolar region thus easing in mouth opening. This combined approach for moderately staged OSMF can be proposed as a viable conservative modality.

Entities:  

Keywords:  Hyaluronidase; Oral Submucous Fibrosis; Third molar; Triamcinolone

Year:  2017        PMID: 29892527      PMCID: PMC5993511          DOI: 10.1016/j.jobcr.2017.06.002

Source DB:  PubMed          Journal:  J Oral Biol Craniofac Res        ISSN: 2212-4268


  6 in total

1.  Pentoxifylline in patients with oral submucous fibrosis-a randomized clinical trial.

Authors:  Namdeo Prabhu; Sanjay S Rao; S M Kotrashetti; Shridhar D Baliga; Seema R Hallikerimath; Punnya V Angadi; Rakhi Issrani
Journal:  J Maxillofac Oral Surg       Date:  2013-09-13

2.  Management of oral submucous fibrosis: a conservative approach.

Authors:  R M Borle; S R Borle
Journal:  J Oral Maxillofac Surg       Date:  1991-08       Impact factor: 1.895

3.  Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases.

Authors:  J N Khanna; N N Andrade
Journal:  Int J Oral Maxillofac Surg       Date:  1995-12       Impact factor: 2.789

4.  Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.

Authors:  R Rajendran; Vidya Rani; Saleem Shaikh
Journal:  Indian J Dent Res       Date:  2006 Oct-Dec

5.  Efficacy of lycopene in the management of oral submucous fibrosis.

Authors:  Abhinav Kumar; Anjana Bagewadi; Vaishali Keluskar; Mohitpal Singh
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-10-24

6.  Retrospective comparison of surgical treatment modalities in 100 patients with oral submucous fibrosis.

Authors:  Divya Mehrotra; R Pradhan; Shalini Gupta
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-03
  6 in total
  2 in total

1.  Efficacy of Prednisolone Mouthwash in Management of Grade III Oral Submucous Fibrosis: A Newer Drug Regimen.

Authors:  Abhay Datarkar; Abhishek Akare; Shikha Tayal
Journal:  J Maxillofac Oral Surg       Date:  2019-05-28

Review 2.  Chemopreventive Agents in Oral Premalignancy: A Medical Management Review.

Authors:  Chintada Suvarna; Nallan Csk Chaitanya; Shaik Ameer; Pavitra Inamdar; Swetha Alugubelli; Alakananda Bhagyanagar
Journal:  J Int Soc Prev Community Dent       Date:  2020-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.